Provista Diagnostics Inc., a Scottsdale, Ariz.-based provider of oncology-based diagnostic tests and clinical laboratory services to the pharmaceutical and biotechnology industries, has raised $2.5m in Series A financing.
Backers include (not disclosed) existing investors.
The company intends to use the capital for expansion of its laboratory capabilities, completion of clinical trials and regulatory submission for dtectDx-Breast (formerly BT Test), general corporate purposes and the development of pipeline products.
Led by Dr. David Reese, President and CEO, Provista develops and commercializes easy to administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes.
Its dtectDx-Breast detects biomarkers using a blood sample which, when used in conjunction with mammography, can help support the early detection of breast cancer.